Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma

Completed · Phase 1

Conditions studied: Brain Stem Glioma, Glioblastoma

In brief

The purpose of the Dendritic Cell Immunotherapy study for patients with glioblastoma and/or brainstem glioma is to determine whether in patients with malignant brain tumors, dendritic cells injected peripherally can reactivate the immune system against the brain tumor.

Key facts

Study ID

NCT00576641

Run by

Cedars-Sinai Medical Center

People needed

22

Starts

2007-05-01

Expected to finish

2012-04-01

Last updated by the study team

2014-10-30

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be HLA -A1 or HLA - A2 positive
• Both male and female of child bearing age must use medically accepted form of birth control
• Confirmed brain stem glioma and glioblastoma with MRI
• Presence of at least one of the antigens by immunohistochemistry
• Karnofsky performance of at least 60%
• On maintenance glucocorticoid therapy at no more 2 mg BID
• Hematologic and chemistry profiles within the parameters of the protocol
• Wash ou periods from previous therapies: 6 weeks from nitrosurea, 4 weeks from chemotherapy, 2 weeks after resolution of Grade 3 or 4 toxicity
• Able to sign IRB approved Informed consent
• Three adults will be treated prior to any study agent administration to subjects younger than 18 years of age

Where it is running

• Cedars Sinai Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.